Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib versus nilotinib after imatinib resistance in chronic-phase CML
NL-OMON43611Phase 3Withdrawn
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ponatinib and nilotinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by ARIAD Pharmaceuticals, Inc. Primary endpoint: Major molecular response by 12 months. Planned start Oct 2015; status: withdrawn.
02
Drugs
ponatinibnilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON43611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43611.